Related references
Note: Only part of the references are listed.Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma
Javeed Iqbal et al.
BLOOD (2010)
Clinical features and prognostic factors of patients with peripheral T cell lymphoma, unspecified
Yuna Lee et al.
ANNALS OF HEMATOLOGY (2009)
High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
M. Nickelsen et al.
ANNALS OF ONCOLOGY (2009)
Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project
Wing-yan Au et al.
BLOOD (2009)
A father and his son with systemic AL amyloidosis
Stina Enqvist et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies
Owen A. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Allogeneic Stem Cell Transplantation Is Able to Induce Long-Term Remissions in Angioimmunoblastic T-Cell Lymphoma: A Retrospective Study From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Charalampia Kyriakou et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified:: report from the International Peripheral T-Cell Lymphoma Project
Kerry J. Savage et al.
BLOOD (2008)
Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials
Nathalie Mourad et al.
BLOOD (2008)
International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes
Julie M. Vose et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas:: a randomised controlled trial (RICOVER-60)
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2008)
Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma:: I.: A randomized dose escalation and feasibility study with bi- and tri-weekly regimens
L. Truemper et al.
ANNALS OF ONCOLOGY (2008)
Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
M. Pfreundschuh et al.
ANNALS OF ONCOLOGY (2008)
High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome—Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Charalampia Kyriakou et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Grappo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial
Andrea Gallamini et al.
BLOOD (2007)
Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience
Hendrik-Tobias Arkenau et al.
HAEMATOLOGICA (2007)
Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study
Jehan Dupuis et al.
BLOOD (2006)
Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study
Hwa Jung Sung et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas
JG Kim et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma
B Glass et al.
BLOOD (2006)
Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (MegaCHOEP) and autologous stem cell transplantation - Early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma
N Schmitz et al.
CANCER (2006)
Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma -: The MD Anderson Cancer Center experience
MP Escalón et al.
CANCER (2005)
The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas
R Sonnen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas:: results of the NHL-B1 trial of the DSHNHL
M Pfreundschuh et al.
BLOOD (2004)
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas:: results of the NHL-B2 trial of the DSHNHL
M Pfreundschuh et al.
BLOOD (2004)
Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification
KJ Savage et al.
ANNALS OF ONCOLOGY (2004)
ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified
RL ten Berge et al.
HISTOPATHOLOGY (2003)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin's Lymphoma Classification Project
T Rudiger et al.
ANNALS OF ONCOLOGY (2002)